Clinical investigators at the Maternal and Child Health Hospital of Hubei Province in Wuhan, China, have documented a complex prenatal genomic case in which parental verification testing for a fetal variant of uncertain significance unexpectedly uncovered a major incidental maternal chromosomal deletion. A thirty-six-year-old pregnant patient, designated G3P1, sought prenatal evaluation at eighteen weeks of gestation during her third pregnancy because of advanced maternal age alongside an adverse obstetric history. Diagnostic amniocentesis analyzed by low-depth whole-genome copy number variation sequencing and G-banded karyotyping identified an isolated four-hundred-and-eighty-kilobase interstitial duplication located at chromosome 5q15 in the male fetus. Because this rare copy number gain lacked definitive pathogenic classification, parental peripheral blood sequencing was carried out solely to establish whether the variant was inherited or had arisen de novo. While paternal analysis revealed normal genomic findings, maternal sequencing confirmed transmission of the 5q15 duplication and simultaneously revealed an unsuspected, pathogenic sixteen-point-sixty-five-megabase heterozygous deletion spanning chromosome Xp22.2 to p21.3.
The patient’s prior reproductive and clinical background formed an essential backdrop to these genomic observations. In 2017, the woman had delivered a healthy full-term female infant through spontaneous vaginal delivery, and this child subsequently reached seven years of age with completely unremarkable neurodevelopment and physical growth without undergoing genetic evaluation. Her menstrual cycles had remained regular until 2021, when her second pregnancy yielded a positive non-invasive prenatal testing screening result through cell-free fetal DNA analysis from maternal blood. According to parental recall, the couple elected to terminate that pregnancy without confirmatory invasive diagnostic testing, and because the procedure and screening occurred at outside institutions, neither the original laboratory screening report nor retained fetal tissues were accessible for retrospective verification. Following that event, the patient experienced twelve months of unprotected intercourse without achieving conception and subsequently received a clinical diagnosis of premature ovarian insufficiency. She later conceived her third pregnancy spontaneously in September 2024, prompting enrollment for comprehensive second-trimester prenatal diagnosis.
Diagnostic testing on the ongoing pregnancy commenced with an amniocentesis procedure conducted at eighteen weeks and three days of gestation. Amniocyte culture yielded a normal male karyotype of 46,XY under standard G-banding protocols. Extracted genomic DNA was simultaneously evaluated through low-depth whole-genome copy number variation sequencing and twenty-one-locus autosomal short tandem repeat linkage analysis with the amelogenin marker on an Applied Biosystems 3500 Dx Genetic Analyzer to verify sample provenance and eliminate maternal cell contamination. High-throughput library construction utilized two-point-five nanograms of template fragmented to approximately two hundred base pairs, followed by adapter ligation, PCR amplification, magnetic bead purification, and single-end sequencing on the NextSeq 550AR platform. Short reads were aligned against the human reference genome GRCh37, unique read counts were calculated across one-hundred-kilobase windows, and local GC bias was adjusted using a locally weighted scatterplot smoothing model. Standardized Z-score thresholds exceeding three for duplications and dipping below negative three for deletions, calibrated against a one-thousand-sample normal karyotype database, delineated the genomic boundaries.
The fetal sequencing analysis identified a 480-kilobase interstitial duplication at cytoband 5q15, formally designated seq [hg19] dup (5)(q15) chr5:g.94580000_95060000dup, exhibiting a copy number of three. This genomic segment encompasses eight distinct protein-coding genes: MCTP1, FAM81B, SKIC3, ARSK, GPR150, RFESD, SPATA9, and RHOBTB3. In accordance with the 2019 joint consensus guidelines established by the American College of Medical Genetics and Genomics and the Clinical Genome Resource, the duplication was classified as a variant of uncertain significance. Database interrogation revealed that the ClinGen dosage sensitivity map contains no triplosensitive genes within this locus, and the Database of Genomic Variants possesses no documented polymorphic record for the fragment. Within the DECIPHER database, the researchers noted only a single overlapping record, case ID331577, involving an individual with an autistic behavioral phenotype. Given the absence of confirmed human disease resulting from increased gene dosage across these eight coding elements, existing population and case-level evidence was judged insufficient to determine clinical pathogenicity.
To clarify the inheritance pattern of the fetal finding, parallel peripheral venous blood sequencing was performed on both parents with the singular clinical objective of segregation analysis. Paternal copy number variation sequencing demonstrated no copy number anomalies across chromosome 5 or the X chromosome, specifically verifying that the 38-year-old father did not harbor the 5q15 duplication. Conversely, maternal sequencing revealed that the mother carried an approximately 500-kilobase duplication at 5q15, designated seq [hg19] dup (5)(q15) chr5:g.94560001_95060000dup with a copy number of three. This maternal copy number gain completely encompassed the fetal duplication, demonstrating direct maternal inheritance. The mother exhibited normal intellectual and physical development without any history of developmental delay or autistic features. In comparative databases, DECIPHER documented another partially overlapping case, ID341303, involving a maternally inherited 289.65-kilobase duplication in a patient with fetal growth retardation. The maternal carrier state provided initial clinical reassurance but did not formally establish benignity.
Unexpectedly, maternal genomic profiling simultaneously uncovered an occult, large constitutional copy number variant on the short arm of the X chromosome. This finding was characterized as a 16.65-megabase interstitial deletion spanning cytogenetic bands Xp22.2 to p21.3, delineated as seq [hg19] del(X)(p22.2p21.3) chrX:g.12210001_28860000del, with a copy number of one. The deleted chromosomal segment encompasses 81 protein-coding genes, including 30 OMIM morbid genes. Among these elements are multiple dosage-sensitive genes associated with severe clinical syndromes and developmental disruption, such as ARX, CDKL5, PHEX, RS1, FANCB, NHS, and OFD1. In line with ACMG and ClinGen classification criteria, this extensive interstitial deletion was designated as definitively pathogenic. Hemizygous males who inherit deletions spanning this X-chromosomal interval typically present with profound neurodevelopmental deficits, intractable seizures, and severe congenital malformations, frequently succumbing during early infancy. Heterozygous female carriers, by contrast, frequently demonstrate no overt somatic symptoms, mirroring the complete absence of syndromic manifestations observed in the proband.
The lack of overt somatic manifestations in the mother raised important biological and clinical questions regarding disease expressivity. In published medical literature, non-manifesting female carriers of extensive Xp deletions are thought to benefit from skewed X-chromosome inactivation, wherein cells preferentially inactivate the structurally abnormal X chromosome. However, the study authors emphasize that because no experimental X-inactivation assay or allele-specific expression study was conducted, this protective mechanism remains strictly hypothetical in this patient. Her reproductive history, however, was notable for premature ovarian insufficiency diagnosed after her 2021 termination. Several protein-coding genes situated within the missing 16.65-megabase segment, including ZFX, USP9X, and PGRMC1, are recognized contributors to normal follicular development and oocyte survival. Although haploinsufficiency of these ovarian genes provides a plausible biological mechanism for diminished ovarian reserve, the investigators caution that no direct molecular evidence or pre- and post-diagnosis ovarian assessments were available, and age-related ovarian decline could not be excluded as a contributing factor.
The discovery of the maternal X-chromosomal deletion also provided fresh retrospective context for the patient’s prior obstetrical experience in 2021. Cell-free fetal DNA screening evaluates circulating fragments derived from maternal peripheral blood, where maternal constitutional copy number variants are a well-recognized cause of aberrant, false-positive screening outputs. Although a 16.65-megabase deletion is sufficiently large to distort cell-free DNA sequencing metrics, the absence of original test documentation or preserved fetal tissue leaves any causal link between the maternal deletion and the 2021 screening result purely inferential. The aborted fetus might have possessed a completely normal karyotype or could have harbored an unrelated chromosomal abnormality. Furthermore, while the patient’s premature ovarian insufficiency was identified following that termination, the medical team affirmed that an uncomplicated elective termination has no established causal link to long-term ovarian failure. Instead, the sequence of events highlights the hazards of electing irreversible pregnancy termination based solely on screening tests without confirmatory diagnostic sampling.
Following comprehensive multidisciplinary genetic counseling, the expectant couple received detailed discussions regarding the biological uncertainties of both variants before deciding to continue the pregnancy. Serial high-resolution obstetric ultrasonography was implemented throughout gestation, incorporating early nuchal translucency assessment, a second-trimester fetal anatomical malformation scan, and third-trimester evaluations of fetal biometry and growth. None of the serial ultrasound examinations revealed fetal structural malformations or signs of intrauterine growth restriction. At 39 weeks of gestation, the patient delivered a male infant through spontaneous vaginal delivery with normal birth weight and no identifiable anomalies on neonatal physical examination. Because an inherited variant of uncertain significance cannot be confirmed as benign based solely on an asymptomatic mother or normal neonatal evaluation, a structured longitudinal monitoring protocol was instituted. This clinical follow-up program is scheduled to track the child’s physical growth, neurodevelopmental milestones, language acquisition, and behavioral patterns through six years of age.
The case underscores essential clinical principles regarding prenatal genomic workflows, segregation analysis, and incidental findings. When parental verification is ordered to trace a fetal variant of uncertain significance, targeted sequencing can unexpectedly uncover occult constitutional abnormalities that carry significant health implications for the parents themselves. The clinical team emphasizes that informed consent protocols for parental testing should explicitly forewarn prospective parents about the potential disclosure of incidental genomic findings. Moreover, the finding provides an objective basis for future family planning discussions, including carrier testing for the couple’s seven-year-old daughter, who faces a theoretical fifty percent risk of inheriting the pathogenic maternal X-chromosomal deletion. Finally, the authors emphasize that non-invasive prenatal testing functions as a screening tool rather than a diagnostic procedure. For individuals with documented parental constitutional chromosomal abnormalities, direct invasive diagnostic modalities such as amniocentesis with copy number variation sequencing remain essential to provide accurate, unconfounded genomic assessments.
Subject of Research: Prenatal genomic diagnosis and parental verification of copy number variants
Article Title: A compound genetic family with a maternal pathogenic Xp22.2-p21.3 deletion and an inherited 5q15 duplication classified as a VUS: prenatal diagnosis, genetic counseling, and retrospective clinical analysis
Article References: Li, H., Li, L., Yu, X., Guo, Q., & Xia, M. (2026). A compound genetic family with a maternal pathogenic Xp22.2-p21.3 deletion and an inherited 5q15 duplication classified as a VUS: prenatal diagnosis, genetic counseling, and retrospective clinical analysis. Frontiers in Genetics, 17, Article 1920571. https://doi.org/10.3389/fgene.2026.1920571
Image Credits: AI Generated
DOI: 10.3389/fgene.2026.1920571
Keywords: copy number variation sequencing, amniocentesis, 5q15 duplication, Xp22.2-p21.3 deletion, variant of uncertain significance, parental verification, prenatal genetic diagnosis, non-invasive prenatal testing, premature ovarian insufficiency, segregation analysis, ACMG/ClinGen criteria, karyotyping, incidental findings, genetic counseling, chromosomal microduplication, X-chromosome inactivation
News Source: Drew Townsend. (November 11, 2026). Prenatal Testing Tracing Fetal Duplication Uncovers Incidental Pathogenic Maternal Deletion. Scienmag.



